Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          

FB825

FB825

FB825 is a novel humanized monoclonal antibody for IgE related allergic disease. Results in Phase I trial implicates that FB825 is considered as a long acting antibody and benefits patients by its pharmaco-economics.

Request for Collaboration
Overview
FB825 (Anti-CεmX;h4B12) was developed by the same inventor who developed anti-IgE therapeutics. FB825 is a humanized monoclonal antibody that targets to the the CεmX domain and kills the membrane IgE+ B lymphocytes by ways of apoptosis and antibody-dependent cellular cytotoxicity (ADCC).

By targeting to mIgE+B lymphocytes, FB825 has a long-lasting effect in down-regulating IgE production. With proven safety and effective pharmacological activity in the clinical trial and the patented intellectual property, FB825 is positioned to be one of the two Anti-CεmX antibodies to be on the market for treatment of IgE-mediated diseases, including atopic dermatitis, allergic asthma, allergic rhinitis, etc.
Application
1. Atopic dermatitis
2. Allergic rhinitis
3. Allergic asthma
Patent Portfolio
Australia, China, Japan, United State and other 9 territories.
People who like this also like
  • ELISA (FMD NSP Ab test)ELISA (FMD NSP Ab test)
  • TiMAX Dental ServiceTiMAX Dental Service
  • ON101- New drug for diabetic foot ulcer healingON101- New drug for diabetic foot ulcer healing
  • PHDC-02PHDC-02
  • FB317FB317
  • Advanced technology in material scienceAdvanced technology in material science
  • CRAM ServicesCRAM Services
  • PipelinePipeline
  • PDL(Precision Dimension Laser)PDL(Precision Dimension Laser)
  • HLX07HLX07